vs

Side-by-side financial comparison of AbbVie (ABBV) and HEALTHCARE SERVICES GROUP INC (HCSG). Click either name above to swap in a different company.

AbbVie is the larger business by last-quarter revenue ($16.6B vs $466.7M, roughly 35.6× HEALTHCARE SERVICES GROUP INC). On growth, AbbVie posted the faster year-over-year revenue change (10.0% vs 6.6%). AbbVie produced more free cash flow last quarter ($4.9B vs $16.0M). Over the past eight quarters, AbbVie's revenue compounded faster (16.2% CAGR vs 5.0%).

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.

Tenet Healthcare Corporation is an American for-profit multinational healthcare services company based in Dallas. Through its brands, subsidiaries, joint ventures, and partnerships including United Surgical Partners International (USPI), the company operates 65 hospitals and over 450 healthcare facilities. Tenet also runs Conifer Health Solutions, which provides healthcare support services to health systems and other clients.

ABBV vs HCSG — Head-to-Head

Bigger by revenue
ABBV
ABBV
35.6× larger
ABBV
$16.6B
$466.7M
HCSG
Growing faster (revenue YoY)
ABBV
ABBV
+3.4% gap
ABBV
10.0%
6.6%
HCSG
More free cash flow
ABBV
ABBV
$4.9B more FCF
ABBV
$4.9B
$16.0M
HCSG
Faster 2-yr revenue CAGR
ABBV
ABBV
Annualised
ABBV
16.2%
5.0%
HCSG

Income Statement — Q4 2025 vs Q4 2025

Metric
ABBV
ABBV
HCSG
HCSG
Revenue
$16.6B
$466.7M
Net Profit
$1.8B
Gross Margin
72.6%
15.4%
Operating Margin
27.3%
6.1%
Net Margin
10.9%
Revenue YoY
10.0%
6.6%
Net Profit YoY
8354.5%
EPS (diluted)
$1.02
$0.43

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABBV
ABBV
HCSG
HCSG
Q4 25
$16.6B
$466.7M
Q3 25
$15.8B
$464.3M
Q2 25
$15.4B
$458.5M
Q1 25
$13.3B
$447.7M
Q4 24
$15.1B
$437.8M
Q3 24
$14.5B
$428.1M
Q2 24
$14.5B
$426.3M
Q1 24
$12.3B
$423.4M
Net Profit
ABBV
ABBV
HCSG
HCSG
Q4 25
$1.8B
Q3 25
$186.0M
$43.0M
Q2 25
$938.0M
$-32.4M
Q1 25
$1.3B
$17.2M
Q4 24
$-22.0M
Q3 24
$1.6B
$14.0M
Q2 24
$1.4B
$-1.8M
Q1 24
$1.4B
$15.3M
Gross Margin
ABBV
ABBV
HCSG
HCSG
Q4 25
72.6%
15.4%
Q3 25
66.4%
20.8%
Q2 25
71.8%
0.6%
Q1 25
70.0%
15.2%
Q4 24
70.9%
13.4%
Q3 24
70.9%
14.8%
Q2 24
70.9%
9.7%
Q1 24
66.7%
15.2%
Operating Margin
ABBV
ABBV
HCSG
HCSG
Q4 25
27.3%
6.1%
Q3 25
12.1%
12.3%
Q2 25
31.7%
-9.1%
Q1 25
28.0%
5.3%
Q4 24
-9.9%
3.4%
Q3 24
26.5%
4.4%
Q2 24
27.6%
-0.5%
Q1 24
22.7%
5.0%
Net Margin
ABBV
ABBV
HCSG
HCSG
Q4 25
10.9%
Q3 25
1.2%
9.3%
Q2 25
6.1%
-7.1%
Q1 25
9.6%
3.8%
Q4 24
-0.1%
Q3 24
10.8%
3.3%
Q2 24
9.5%
-0.4%
Q1 24
11.1%
3.6%
EPS (diluted)
ABBV
ABBV
HCSG
HCSG
Q4 25
$1.02
$0.43
Q3 25
$0.10
$0.59
Q2 25
$0.52
$-0.44
Q1 25
$0.72
$0.23
Q4 24
$-0.03
$0.15
Q3 24
$0.88
$0.19
Q2 24
$0.77
$-0.02
Q1 24
$0.77
$0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABBV
ABBV
HCSG
HCSG
Cash + ST InvestmentsLiquidity on hand
$5.3B
$168.0M
Total DebtLower is stronger
$58.9B
Stockholders' EquityBook value
$-3.3B
$510.2M
Total Assets
$134.0B
$794.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABBV
ABBV
HCSG
HCSG
Q4 25
$5.3B
$168.0M
Q3 25
$5.7B
$177.5M
Q2 25
$6.5B
$134.5M
Q1 25
$5.2B
$114.8M
Q4 24
$5.6B
$107.3M
Q3 24
$7.3B
$103.8M
Q2 24
$13.2B
$105.6M
Q1 24
$18.1B
$104.9M
Total Debt
ABBV
ABBV
HCSG
HCSG
Q4 25
$58.9B
Q3 25
$63.0B
Q2 25
$63.0B
Q1 25
$64.5B
Q4 24
$60.3B
Q3 24
$58.5B
Q2 24
$58.0B
Q1 24
$63.8B
Stockholders' Equity
ABBV
ABBV
HCSG
HCSG
Q4 25
$-3.3B
$510.2M
Q3 25
$-2.6B
$496.0M
Q2 25
$-183.0M
$477.0M
Q1 25
$1.4B
$514.2M
Q4 24
$3.3B
$499.9M
Q3 24
$6.0B
$488.7M
Q2 24
$6.8B
$471.4M
Q1 24
$8.0B
$474.6M
Total Assets
ABBV
ABBV
HCSG
HCSG
Q4 25
$134.0B
$794.3M
Q3 25
$133.9B
$804.3M
Q2 25
$137.2B
$802.2M
Q1 25
$136.2B
$823.0M
Q4 24
$135.2B
$802.8M
Q3 24
$143.4B
$805.8M
Q2 24
$141.9B
$799.7M
Q1 24
$148.9B
$803.9M
Debt / Equity
ABBV
ABBV
HCSG
HCSG
Q4 25
Q3 25
Q2 25
Q1 25
45.44×
Q4 24
18.15×
Q3 24
9.70×
Q2 24
8.56×
Q1 24
7.97×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABBV
ABBV
HCSG
HCSG
Operating Cash FlowLast quarter
$5.2B
$17.4M
Free Cash FlowOCF − Capex
$4.9B
$16.0M
FCF MarginFCF / Revenue
29.4%
3.4%
Capex IntensityCapex / Revenue
2.0%
0.3%
Cash ConversionOCF / Net Profit
2.87×
TTM Free Cash FlowTrailing 4 quarters
$17.8B
$139.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABBV
ABBV
HCSG
HCSG
Q4 25
$5.2B
$17.4M
Q3 25
$7.0B
$71.3M
Q2 25
$5.2B
$28.8M
Q1 25
$1.6B
$27.5M
Q4 24
$7.0B
$36.2M
Q3 24
$5.4B
$4.3M
Q2 24
$2.3B
$16.3M
Q1 24
$4.0B
$-26.0M
Free Cash Flow
ABBV
ABBV
HCSG
HCSG
Q4 25
$4.9B
$16.0M
Q3 25
$6.6B
$70.0M
Q2 25
$4.9B
$27.4M
Q1 25
$1.4B
$25.8M
Q4 24
$6.8B
$34.8M
Q3 24
$5.2B
$2.9M
Q2 24
$2.0B
$15.0M
Q1 24
$3.8B
$-28.2M
FCF Margin
ABBV
ABBV
HCSG
HCSG
Q4 25
29.4%
3.4%
Q3 25
42.1%
15.1%
Q2 25
31.7%
6.0%
Q1 25
10.5%
5.8%
Q4 24
44.7%
7.9%
Q3 24
35.9%
0.7%
Q2 24
14.0%
3.5%
Q1 24
31.3%
-6.7%
Capex Intensity
ABBV
ABBV
HCSG
HCSG
Q4 25
2.0%
0.3%
Q3 25
2.4%
0.3%
Q2 25
1.7%
0.3%
Q1 25
1.8%
0.4%
Q4 24
1.9%
0.3%
Q3 24
1.7%
0.3%
Q2 24
1.7%
0.3%
Q1 24
1.6%
0.5%
Cash Conversion
ABBV
ABBV
HCSG
HCSG
Q4 25
2.87×
Q3 25
37.76×
1.66×
Q2 25
5.49×
Q1 25
1.27×
1.60×
Q4 24
Q3 24
3.49×
0.31×
Q2 24
1.66×
Q1 24
2.95×
-1.70×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons